{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:46:36Z","timestamp":1789904796579,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.eplepsyres.2013.06.011","type":"journal-article","created":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T15:45:51Z","timestamp":1375112751000},"page":"446-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Valproate reduces collagen and osteonectin in cultured bone cells"],"prefix":"10.1016","volume":"106","author":[{"given":"Emma L.","family":"Humphrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn E.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi R.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0005","first-page":"435","article-title":"Pharmacodynamic properties of N-dipropylacetic acid","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1176\/ajp.138.2.256","article-title":"Therapeutic effect of valproate in mania","volume":"138","author":"Emrich","year":"1981","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0015","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00018-007-7079-x","article-title":"The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?","volume":"64","author":"Rosenberg","year":"2007","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1042\/BST0371126","article-title":"Structure\u2013function studies for the panacea, valproic acid","volume":"37","author":"Terbach","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tips.2007.02.005","article-title":"Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms","volume":"28","author":"Calabresi","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2119\/molmed.2011.00069","article-title":"Inhibition of histone deacetylases in inflammatory bowel diseases","volume":"17","author":"Glauben","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/14740331003636475","article-title":"Bone loss associated with use of antiepileptic drugs","volume":"9","author":"Nakken","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.amjopharm.2010.02.003","article-title":"A review of the effect of anticonvulsant medications on bone mineral density and fracture risk","volume":"8","author":"Lee","year":"2010","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0045","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0050","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0055","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1021\/pr1005263","article-title":"Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells","volume":"9","author":"Fuller","year":"2010","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbagen.2004.01.008","article-title":"A lamin A\/C beta-strand containing the site of lipodystrophy mutations is a major surface epitope for a new panel of monoclonal antibodies","volume":"1671","author":"Manilal","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jcb.10259","article-title":"Further characterization of human fetal osteoblastic hFOB 1.19 and hFOB\/ER alpha cells: bone formation in vivo and karyotype analysis using multicolour fluorescent in situ hybridisation","volume":"87","author":"Subramaniam","year":"2002","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jbmr.5650100203","article-title":"Development and characterization of a conditionally immortalized human fetal osteoblastic cell line","volume":"10","author":"Harris","year":"1995","journal-title":"J. Bone Miner Res."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0070","first-page":"229","article-title":"Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome","volume":"54","author":"Jacobsen","year":"1993","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0075","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/000456320203900602","article-title":"Receptor activator from nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses\/potential therapeutic agents and biochemical markers","volume":"39","author":"Buckley","year":"2002","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0080","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jcb.10742","article-title":"Phenylbutyrate decreases type I collagen production in human lung fibroblasts","volume":"91","author":"Rishikof","year":"2004","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0085","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2013.06.011_bib0090","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1210\/en.2002-221044","article-title":"Osteonectin-null mutation compromises osteoblast formation, maturation, and survival","volume":"144","author":"Delany","year":"2003","journal-title":"Endocrinology"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113001757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113001757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:30:06Z","timestamp":1760275806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121113001757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0920121113001757"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.06.011","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproate reduces collagen and osteonectin in cultured bone cells","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}